Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials

IMPORTANCE: Immune-related adverse events (irAEs) arising from immune checkpoint inhibitor (ICI) cancer therapy may potentially predict improved outcomes. OBJECTIVE: To evaluate the association between irAEs and atezolizumab efficacy in patients with advanced non–small cell lung cancer (NSCLC) using...

Descripción completa

Detalles Bibliográficos
Autores principales: Socinski, Mark A., Jotte, Robert M., Cappuzzo, Federico, Nishio, Makoto, Mok, Tony S. K., Reck, Martin, Finley, Gene G., Kaul, Monika D., Yu, Wei, Paranthaman, Nindhana, Bāra, Ilze, West, Howard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936386/
https://www.ncbi.nlm.nih.gov/pubmed/36795388
http://dx.doi.org/10.1001/jamaoncol.2022.7711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936386/
https://www.ncbi.nlm.nih.gov/pubmed/36795388
http://dx.doi.org/10.1001/jamaoncol.2022.7711

Ejemplares similares